BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Mabwell begins first human trial of iron-regulating drug 9MW3011

The study (CTR20230046) is a phase 1, single center, randomized, double-blind，placebo-controlled, ascending dose study to evaluate the safety, ...

March 15, 2023 | News

Servier's Phase 3 INDIGO trial shows positive results for vorasidenib in IDH-mutant Glioma

Clinically meaningful achievement of primary and secondary endpoints is first major advance in treatment of low-grade glioma in more than 20 years Endpo...

March 15, 2023 | News

Simcere Zaiming partners with Merck for SIM0235 clinical trial in advanced tumors and lymphoma

Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an in...

March 15, 2023 | News

Akeso, based in Hong Kong, completes patient enrollment for Phase III clinical trial of Cadonilimab in the treatment of gastric cancer.

Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-sp...

March 14, 2023 | News

Antengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China

- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Assoc...

March 14, 2023 | News

Telix's Revolutionary Kidney Cancer Imaging Study Takes Center Stage at EAU's 'Game Changing' Session

The results were featured in a "Game Changing" oral session delivered by Professor Dr. Peter Mulders from Radboud University Medical Centre (Neth...

March 14, 2023 | News

H1 Launches Advanced Diversity Insights and Clinical Trial Performance Insights

H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the availability of indication-level ...

March 13, 2023 | News

Boan Biotech Completes Patient Enrollment for Aflibercept Trial in China

Aflibercept is a homodimeric fusion protein consisting of portions of human vascular endothelial growth factor receptor (VEGFR) extracellular domains (VEGF...

March 13, 2023 | News

Telix to Present ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EAU

Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (Clinic...

March 09, 2023 | News

JW Therapeutics Starts Clinical Trial of Carteyva® for High-Risk Large B-Cell Lymphoma

High-risk large B-cell lymphoma includes large B-cell lymphoma with International Prognostic Index (IPI) score ≥3, and high-grade B-cell lymphoma (HGBL)...

March 09, 2023 | News

Hummingbird Bioscience licenses Cancer Research UK's clinical trial results to support HMBD-001 development.

The Phase 1/2a clinical trial in the United Kingdom is being sponsored and managed by CRUK's Centre for Drug Development and led by Chief Investi...

March 06, 2023 | News

Harbour BioMed's Batoclimab Shows Positive Results in Phase III Trial for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...

March 06, 2023 | News

C2i Genomics Expands to Japan, Announces Collab with Riken Genesis

The collaboration will expand C2i’s global reach and bring MRD cancer monitoring capabilities for solid tumors to Japan C2i Genomics...

March 03, 2023 | News

Celebrating International Women's Day: Recognizing 12 Leading Women in Clinical Trials in APAC

As BioPharma APAC celebrates International Women's Day on March 8, it's time to recognize the remarkable contributions of women in clinical trials. These w...

March 03, 2023 | News

Stay Connected